UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)

Annals of oncology, 2015-03, Vol.26 (3), p.561-567

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck

European journal of cancer (1990), 2013-09, Vol.49 (13), p.2877-2883

2013

Link zum Volltext

Verfügbarkeit prüfen

3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

European journal of cancer (1990), 2015-09, Vol.51, p.S708-S708

2015

Link zum Volltext

Verfügbarkeit prüfen

3 Pre-therapeutic ex-vivo repair kinetics of cisplatin–DNA-adducts in circulating tumor cells (CTC) as platinum resistance test

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S2-S2

2013

Link zum Volltext

Verfügbarkeit prüfen

Multimodale Therapie des lokal-fortgeschrittenen nichtkleinzelligen Lungenkarzinoms

Der Onkologe, 2011-08, Vol.17 (8), p.691-701

2011

Link zum Volltext

Verfügbarkeit prüfen

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Annals of oncology, 2016-10, Vol.27 (10), p.1895-1902

2016

Link zum Volltext

Verfügbarkeit prüfen

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

Annals of oncology, 2014-03, Vol.25 (3), p.682-688

2014

Link zum Volltext

Verfügbarkeit prüfen

A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer

Annals of oncology, 2011-08, Vol.22 (8), p.1798-1804

2011

Link zum Volltext

Verfügbarkeit prüfen

1542P First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

Annals of oncology, 2022-09, Vol.33, p.S1252

2022

Link zum Volltext

Verfügbarkeit prüfen

707TiP Postoperative adjuvant radiochemotherapy (aRCH) with cisplatin versus aRCH with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma: The ADRISK trial

Annals of oncology, 2022-09, Vol.33, p.S866

2022

Link zum Volltext

Verfügbarkeit prüfen

1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data

Annals of oncology, 2023-10, Vol.34, p.S1060-S1060

2023

Link zum Volltext

Verfügbarkeit prüfen

Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten

Onkologie (Heidelberg, Germany), 2013-10, Vol.19 (10), p.821-834

2013

Link zum Volltext

Verfügbarkeit prüfen

MA06.08 Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLC

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S65

2022

Link zum Volltext

Verfügbarkeit prüfen

EP04.01-016 First Comprehensive Lung Cancer Long-Term Survivorship Analysis - Late Toxicities and Overall Survival

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S252-S253

2022

Link zum Volltext

Verfügbarkeit prüfen

EP04.02-005 First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S262

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie

Oncology, 2013-01, Vol.84 (5), p.284-289

2013

Link zum Volltext

Verfügbarkeit prüfen

Immuntherapie von Kopf-Hals-Karzinomen: Aktuelle Entwicklungen

HNO, 2013-09, Vol.61 (7), p.559-572

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)

Annals of oncology, 2012-03, Vol.23 (3), p.678-687

2012

Link zum Volltext

Verfügbarkeit prüfen

9124 Phase I trial of sagopilone in combination with cisplatin as 1st-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC)

European journal of cancer supplements, 2009, Vol.7 (2), p.542-542

2009

Link zum Volltext

Verfügbarkeit prüfen

1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours

European journal of cancer supplements, 2009, Vol.7 (2), p.129-129

2009

Link zum Volltext

Verfügbarkeit prüfen

Everolimus in the Sequence after Failure of Vegfr-Directed Therapy in MRCC - A Retrospective Analysis

Annals of oncology, 2012-09, Vol.23, p.ix288-ix289

2012

Link zum Volltext

Verfügbarkeit prüfen

Impact of EGFR Mutation Status on Clinical Benefit from BIBW 2992 in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) Progressing After Chemotherapy (CTX) and Erlotinib (E) or Gefitinib (G) – A Single Center Experience

Annals of oncology, 2012-09, Vol.23, p.ix437-ix438

2012

Link zum Volltext

Verfügbarkeit prüfen

Addition of Darbepoetin Alfa to Sequential High Dose Vip Chemotherapy for Patients with Advanced Metastatic Germ Cell Cancer

Annals of oncology, 2012-09, Vol.23, p.ix284

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(31)

Sprache

Erscheinungsjahr

n.n

Zeitschrift / Serie

Annals Of Oncology
(17)
Journal Of Thoracic Oncology
(4)
Der Onkologe
(2)
European Journal Of Cancer
(2)
European Journal Of Cancer Supplements
(2)
Onkologie
(2)
Hno
(1)
Lung Cancer
(1)
Oncology
(1)

4 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

TEMHEAD: a single-arm multicentre phase II study of temsirolimus in platin- and cetuximab refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) of the German SCCHN Group (AIO)

Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck

3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)

3 Pre-therapeutic ex-vivo repair kinetics of cisplatin–DNA-adducts in circulating tumor cells (CTC) as platinum resistance test

Multimodale Therapie des lokal-fortgeschrittenen nichtkleinzelligen Lungenkarzinoms

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part)

A German multicenter, randomized phase III trial comparing irinotecan–carboplatin with etoposide–carboplatin as first-line therapy for extensive-disease small-cell lung cancer

1542P First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

707TiP Postoperative adjuvant radiochemotherapy (aRCH) with cisplatin versus aRCH with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma: The ADRISK trial

927P Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study

1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data

680P HANNA: Real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany

Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten Medikamenten

MA06.08 Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLC

EP04.01-016 First Comprehensive Lung Cancer Long-Term Survivorship Analysis - Late Toxicities and Overall Survival

EP04.02-005 First Comprehensive Lung Cancer Long-Term Survivorship Program - Late Toxicities and Overall Survival

Phase II Study of Cetuximab in Combination with Docetaxel in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck after Platinum-Containing Therapy: A Multicenter Study of the Arbeitsgemeinschaft Internistische Onkologie

Immuntherapie von Kopf-Hals-Karzinomen: Aktuelle Entwicklungen

Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC)

9124 Phase I trial of sagopilone in combination with cisplatin as 1st-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC)

1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours

Everolimus in the Sequence after Failure of Vegfr-Directed Therapy in MRCC - A Retrospective Analysis

Impact of EGFR Mutation Status on Clinical Benefit from BIBW 2992 in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC) Progressing After Chemotherapy (CTX) and Erlotinib (E) or Gefitinib (G) – A Single Center Experience

Addition of Darbepoetin Alfa to Sequential High Dose Vip Chemotherapy for Patients with Advanced Metastatic Germ Cell Cancer

Suchergebnisse filtern